search

Active clinical trials for "Glioblastoma"

Results 131-140 of 1616

A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors

GlioblastomaMelanoma Stage IV12 more

This is an open-label, two-part, phase 1-2 dose-finding study designed to determine the safety, tolerability, PK, PD, and proof-of-concept efficacy of ST101 administered IV in patients with advanced solid tumors. The study consists of two phases: a phase 1 dose escalation/regimen exploration phase and a phase 2 expansion phase.

Recruiting31 enrollment criteria

Mycophenolate Mofetil Combined With Radiation Therapy in Glioblastoma

Recurrent GlioblastomaRecurrent Gliosarcoma6 more

This is a phase 0/1 dose-escalation trial to determine the maximum tolerated dose of Mycophenolate Mofetil (MMF) when administered with radiation, in patients with glioblastoma or gliosarcoma.

Recruiting31 enrollment criteria

Tamoxifen Versus Etoposide After First Recurrence in GBM Patients

Glioblastoma Multiforme

The investigator propose a single-center randomized phase II controlled study designed to compare the management of first recurrence of GBM using etoposide versus tamoxifen.

Recruiting23 enrollment criteria

Analyzing Pulsed Reduced Dose Radiotherapy in Upfront Glioblastoma

Glioblastoma

The primary protocol objective is to assess the impact of substituting pulsed reduced dose radiotherapy (pRDR) for standard radiation therapy in the upfront treatment of glioblastoma (GBM) on disease progression.

Recruiting37 enrollment criteria

Glioblastoma Radiotherapy Using IMRT or Proton Beams

Glioblastoma

Radiation therapy is an integral part of the multimodal primary therapy of glioblastomas. As the overall prognosis in this tumor entity remains unfavorable, current research is focused on additional drug therapies, which are often accompanied by increases in toxicity. By using proton beams instead of photon beams, it is possible to protect large parts of the brain which are not affected by the tumor more effectively. An initial retrospective matched-pair analysis showed that this theoretical physical benefit is also clinically associated with a reduction in toxicity during therapy and in the first few months thereafter. The aim of the GRIPS study is to prospectively test this clinical benefit in a randomized, open-label Phase III study. Patients are treated in the study using either modern photon radiation techniques (standard arm) or proton beams (experimental arm). The primary endpoint is the cumulative toxicity CTC grade 2 and higher in the first 4 months. Secondary endpoints include overall survival, progression-free survival, quality of life, and neurocognition.

Recruiting11 enrollment criteria

Study of DSP-0390 in Patients With Recurrent High-Grade Glioma

High Grade GliomaGlioblastoma Multiforme

This is a study of DSP-0390 in patients with recurrent high grade glioma.

Recruiting26 enrollment criteria

B7-H3 CAR-T for Recurrent or Refractory Glioblastoma

Recurrent GlioblastomaRefractory Glioblastoma

This is a randomized, parallel-arm, phase I/II study to evaluate the safety and efficacy of B7-H3 CAR-T in between Temozolomide cycles comparing to Temozolomide alone in treating patients with glioblastoma that has come back or does not respond to the standard treatment. The antigen B7-H3 is highly expressed in glioblastoma of a subset of patients. B7-H3 CAR-T, made from isolated patient peripheral blood mononuclear cells, can specifically attack patient glioblastoma cells that expressing B7-H3.

Recruiting36 enrollment criteria

Supramarginal Resection in Glioblastoma Guided by Artificial Intelligence

Glioblastoma

Glioblastomas are the most common and poorly prognostic primary brain neoplasms. Despite advances in surgical techniques and chemotherapy, the median survival time for these patients remains less than 15 months. This highlights the need for more effective treatments and improved prognostic tools. The globally accepted surgical strategy currently consists of achieving the maximum safe resection of the enhancing tumor volume. However, the non-enhancing peritumoral region contains viable cells that cause the inevitable recurrence that these patients face. Clinicians currently lack an imaging tool or modality to differentiate neoplastic infiltration in the peritumoral region from vasogenic edema. In addition, it is not always feasible to include all the T2-FLAIR signal alterations surrounding the enhancing tumor in the surgical planning due to the proximity of eloquent areas and the higher risk of postoperative deficits. However, the investigators have developed a model to predict regions of recurrence based on machine learning and MRI radiomic features that have been trained and evaluated in a multi-institutional cohort. The investigators aim to analyze whether an adjusted supramarginal resection guided by these new recurrence probability maps improves survival in selected patients with glioblastoma.

Recruiting10 enrollment criteria

Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer

Brain CancerGlioblastoma3 more

The purpose of this study is to find out how much tratuzumab deruxtecan (T-DXd) can penetrate the tumor when injected into the body, and whether T-DXd may be an effective treatment for brain cancers that express the HER2 protein.

Recruiting81 enrollment criteria

NBM-BMX Administered Orally to Patients With Solid Tumors or Newly Diagnosed Glioblastoma

Malignant NeoplasmMalignant Neoplasm of Brain

NBM-BMX is an orally available new chemical entity to inhibit histone deacetylases 8 (HDAC8) activity specifically, being developed as a potential anti-cancer therapeutic by NatureWise. This study aims to evaluate the safety, pharmacokinetics, and preliminary efficacy of NBM-BMX as monotherapy in subjects with advanced solid tumors or combination with the standard of care treatment in subjects with newly diagnosed glioblastoma.

Recruiting55 enrollment criteria
1...131415...162

Need Help? Contact our team!


We'll reach out to this number within 24 hrs